Crizanlizumab
Adakveo (crizanlizumab) is a prescription biologic medication manufactured by Novartis Pharmaceuticals Corporation. It acts as a P-selectin blocker to help manage certain conditions. Administered intravenously as an injection at 10 mg/mL strength. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[ "009:10" ] |
| contactPoint |
{ "fn": "Division of Drug Information", "@type": "vcard:Contact", "hasEmail": "mailto:druginfo@fda.hhs.gov" } |
| description | Adakveo (crizanlizumab) is a prescription biologic medication manufactured by Novartis Pharmaceuticals Corporation. It acts as a P-selectin blocker to help manage certain conditions. Administered intravenously as an injection at 10 mg/mL strength. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[ { "@type": "dcat:Distribution", "title": "Crizanlizumab", "mediaType": "text/html", "description": " Access the FDA dataset for Crizanlizumab — ANDA 761128 submitted by Mylan Institutional LLC ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761128" } ] |
| identifier | ANDA761128 |
| issued | 2016-09-16 |
| keyword |
[ "drug-safety", "fda", "health-care", "medications", "prescription-drugs" ] |
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[ "009:002" ] |
| publisher |
{ "name": "U.S. Food and Drug Administration", "@type": "org:Organization" } |
| theme |
[ "FDA" ] |
| title | Crizanlizumab |
